Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 944-952

  Sylvester, John E ^a,b,e   Blasko, John C ^a   Grimm, Peter D ^a   Meier, Robert ^a   Malmgren, Judith A ^c,d  

^a SWEDISH MEDICAL CENTER   (United States)

^b Stevens Hospital   (United States)

^c HealthStat Consulting Inc   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Seattle Prostate Institute   (United States)

Author keywords

Brachytherapy; Prostate; Prostatic neoplasms; Radiotherapy

Indexed keywords

BIOCHEMISTRY; DIAGNOSIS; RADIOTHERAPY; TUMORS;

BRACHYTHERAPY;

ONCOLOGY;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0142217892     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00739-9     Document Type: Article

References (27)

1. Sylvester J., Blasko J.C., Grimm P., et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol. 66:1997;65-75.
2. Hilaris B, Fuks Z, Nori D, et al.Interstitial irradiation in prostatic cancer: Report of 10-year results. In: Sauer R, editor. Interventional radiation therapy techniques/brachytherapy. Berlin: Springer-Verlag; 1991. p. 235.
3. Nath R., Roberts K., Ng M., et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys. 25:1998;2293-2307.
4. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
5. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 50:2001;605-614.
6. Grimm P., Blasko J., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
7. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
8. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 5:1999;301-306.
9. Dattoli M., Wallner K., True L., et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 45:1999;853-856.
10. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. [Review] Cancer. 83:1998;989-1001.
11. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol. 13:1997;454-460.
12. Beyer D.C., Priestley J.B. Biochemical disease-free survival following I-125 prostate implantation. [Abstract 1062] Int J Radiat Oncol Biol Phys. 32:(Suppl):1995;254.
13. Sylvester J., Blasko J.C., Grimm P.D., et al. Neoadjuvant androgen ablation combined with external beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer. Mol Urol. 3:1999;231-236.
14. Sylvester J., Blasko J.C., Grimm P.D., et al. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer a matched subset analysis. Mol Urol. 4:2000;155-159. discussion, 161.
15. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 51:2001;41-48.
16. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 49:2001;1297-3003.
17. Lee L.N., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;444-452.
18. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 18:2000;1164-1172.
19. D'Amico AV. Personal communication, 2002.
20. Grimm P.D., Blasko J.C., Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer: Technical concepts in planning, operative technique, and evaluation. Schellhammer P.F. New techniques in prostate surgery. Vol 2. 1994;113-126 W. B. Saunders Co, Philadelphia.
21. Epstein J. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol. 24:2000;477-478.
22. Steinberg D., Sauvageot J., Piantadosi S., et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 21:1997;566-576.
23. Iczkowski K.A., Bostwick D.G. The pathologist as optimist cancer grade deflation in prostatic needle biopsies. [Editorial] Am J Surg Pathol. 22:1998;1169-1170.
24. Critz F.A., Levinson A.K., Williams W.H., et al. Simultaneous radiotherapy for prostate cancer 125I prostate implant followed by external-beam radiation. [See comments] Cancer J Sci Am. 4:1998;359-363.
25. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 37:1997;1043-1052.
26. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
27. Sylvester J.E., Blasko J.C., Grimm P.D., et al. 10-year biochemical relapse-free survival following brachytherapy with external beam radiotherapy for patients with localized prostate cancer The Seattle experience. [Abstract] Int J Radiat Oncol Biol Phys. 54:(Suppl):2002;38.